Merck & Co. to acquire ArQule to advance leadership in oncology
Category: #health  By Mateen Dalal  Date: 2019-12-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck & Co. to acquire ArQule to advance leadership in oncology

Merck, a renowned American pharmaceutical company also known as MSD outside Canada and the United States, reportedly announced the acquisition of ArQule, a US-based biopharmaceutical firm focused on finding novel therapies for cancer treatment. The company would acquire ArQule for an equity value of about $2.7 billion.

President at Merck Research Laboratories, Dr. Roger M. Perlmutter stated that ArQule’s efforts on precision medicine have brought multiple clinical-stage oral kinase inhibitors having important and novel properties.

The ArQule acquisition would strengthen the company’s pipeline with the addition of these strategic assets which includes ARQ 531. ARQ 531 is a compelling candidate for B-cell malignancies treatment. Final outcomes from the Phase 1 trial of ARQ 531 would be showcased on December 9, 2019, during the 61st ASH (American Society of Hematology) Annual Meeting & Exposition taking place in Orlando, Florida.

BTK inhibition has proven to stop B-cell receptor signaling which is crucial for the survival and expansion of leukemic cells in several B-cell malignancies. ARQ 531 is a reversible, highly selective inhibitor that blocks wild-type BTK as well as C481S mutant form of the enzyme that is generally linked with resistance to some other BTK inhibitors.

CEO at ArQule, Paolo Pucci stated that the company is proud that Merck has acknowledged the contributions made by ArQule to the precision medicine field along with its scientific collaborators.

Pucci further added that with this acquisition, the company’s pipeline would benefit from Merck’s extensive capabilities and determined engagement to help the patients who the company has always worked to serve.

According to the terms of the acquisition, Merck, from one of its subsidiaries, would initiate a tender offer for the acquisition of all ArQule’s outstanding shares. The tender offer closing would be subject to certain conditions. These conditions include the tender of shares demonstrating at least a majority of the total number of the company’s outstanding shares, the completion of the waiting period in the Hart-Scott-Rodino Antitrust Improvements Act as well as other customary conditions.

After the successful completion of the tender agreement, Merck’s acquisition subsidiary would be integrated with ArQule. Furthermore, any leftover shares of ArQule’s common stock would be canceled and further converted into the right to receive the same $20 each share price which would be payable in the tender offer. The acquisition deal is estimated to complete early during the first quarter of 2020.

 

Source credit: https://www.mrknewsroom.com/news-release/oncology/merck-acquire-arqule-advancing-leadership-oncology

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

40% of COVID-19 patients are asymptomatic, a new CDC report claims
40% of COVID-19 patients are asymptomatic, a new CDC report claims
By Mateen Dalal

The ongoing coronavirus pandemic has wreaked havoc worldwide. Dismissed as a slight by the world initially, the virus shocked the scientific and medical communities alike, with the rapid rate of spreading. Very little information about the novel coro...

AI-centric study abroad platform Edvoy launched by IEC Abroad in India
AI-centric study abroad platform Edvoy launched by IEC Abroad in India
By Mateen Dalal

AI oriented study abroad platform, Edvoy, based out of UK, has reportedly declared its launch in India.  Edvoy, created by IEC Abroad, is a free digital platform that provides impartial advice, support, and content to prospective international s...

Centuria announces Augusta Capital takeover offer to be unconditional
Centuria announces Augusta Capital takeover offer to be unconditional
By Mateen Dalal

  Acceptance to takeover represent 65.86% of Augusta’s shares Takeover provide shareholders with NZ$0.22 in cash and 0.392 Centuria stapled securities for every share of Augusta Centuria’s assets under management will increase b...